CPT1A and neoplasm: Pharmacological inhibition of the PCK/CPT1A significantly suppressed tumor growth in 18F-FDG-PET/CT-negative gastric cancers, as demonstrated in both cell-derived xenograft (CDX) and patient-derived xenograft (PDX) models.